OncoMatch/Clinical Trials/NCT05900882
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Is NCT05900882 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Selinexor and Bortezomib for multiple myeloma.
Treatment: Selinexor · Bortezomib · Lenalidomide · Dexamethasone — The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.0×10^9/L, HGB ≥ 75×10^9/L, PLT ≥ 50×10^9/L (≥50% of bone marrow nucleated cells are plasma cells)
Kidney function
creatinine clearance ≥ 30 ml/min
Liver function
ALT and AST < 3 times the upper limit of normal (ULN); serum bilirubin < 1.5 × ULN
Cardiac function
No active, unstable cardiovascular dysfunction: symptomatic ischemia; uncontrolled, clinically significant conduction abnormalities (except antiarrhythmic ventricular tachycardia); NYHA Class III-IV or LVEF <40%; myocardial infarction within 3 months before C1D1
ANC≥1.0*10^9/L, HGB≥75*10^9/L, PLT≥50*10^9/L (≥50% of bone marrow nucleated cells are plasma cells). Significant hepatic dysfunction (ALT and AST ≥ 3 times the upper limit of normal (ULN)). Serum bilirubin≥1.5 × ULN. creatinine clearance <30 ml/min. Active, unstable cardiovascular dysfunction: a. symptomatic ischemia; b. Uncontrolled, clinically significant conduction abnormalities (except antiarrhythmic ventricular tachycardia), but patients with first-degree atrioventricular block or asymptomatic left anterior bundle/right fascicular block cannot be excluded. c. New York Heart Association (NYHA) Class III - IV or left ventricular ejection fraction (LVEF) <40%; d. Myocardial infarction Within 3 months before C1D1.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify